<DOC>
	<DOCNO>NCT01503866</DOCNO>
	<brief_summary>The purpose study determine absorption excretion kinetics bardoxolone methyl determine characterize metabolite present plasma , urine feces men follow single oral 20 mg [ 14C ] -bardoxolone methyl .</brief_summary>
	<brief_title>A Phase I Study Investigate Absorption , Metabolism Excretion Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Males , age 18 45 year , inclusive ; Males either sterile agree use Checkin ( Day 1 ) 45 day follow Clinic Discharge , follow approve method contraception : male condom spermicide ; sterile sexual partner ; use female sexual partner intrauterine device spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ( eg , NuvaRing ) ; diaphragm spermicide ; cervical cap spermicide ; oral , implantable , transdermal , injectable contraceptive ; Within BMI range 19 31 kg/m2 , inclusive ; Willing able give write informed consent study participation provide consent access medical data accord appropriate local data protection legislation , allow authorization access medical record describe event capture endpoint ; Willing able cooperate aspect protocol ; least 1 regular bowel movement per day . Participated another clinical trial investigational drug ( medical device ) within 30 day prior study entry , currently participate another trial investigational drug ( medical device ) ; Participated [ 14C ] study within last 6 month prior Checkin ( Day 1 ) study . The total exposure previous study must within recommend level consider safe ( per 21 Code Federal Regulations [ CFR ] 361.1 2010 ) , example , less 5,000 mrem/year whole body exposure ; Exposure significant radiation within 12 month prior Checkin ( Day 1 ) ; Any condition possibly affect absorption , distribution , metabolism , excretion drug may confound analysis conduct study ; Known hypersensitivity component formulation study drug , bardoxolone methyl ; Evidence history concurrent clinically significant allergic , hematological , endocrine , immunological , renal , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease judgment Investigator could potentially either pose health risk subject study influence study outcome ; Evidence hepatic biliary dysfunction include elevation total bilirubin , direct bilirubin , AST , ALT , GGT , lactate dehydrogenase , alkaline phosphatase level great upper limit normal ; Positive test result human immunodeficiency virus type 1 2 antibody , hepatitis B surface antigen , hepatitis C virus antibody Screening ; Any medical dental procedure , matter minor , plan anticipate occur conduct study ; History drug alcohol abuse dependence within last year ; Any vaccination within 30 day prior Day 1 throughout study ; Use need systemic drug ( ) include vitamin herbal preparation within 30 day prior Day 1 study ; Use aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) , acetaminophen within 5 day prior ingestion study drug ; use aspirin NSAIDs ( acetaminophen ) allow confinement isolate episode pain discretion Investigator ; Donation receipt blood blood component within 4 week prior Screening ; Any diagnostic intervention procedure require contrast agent within 30 day prior Screening ; Sustained systolic blood pressure &gt; 140 mmHg &lt; 100 mmHg diastolic blood pressure &gt; 95 mmHg Screening baseline measure 5 minute sit position ; A pulse rate rest sit position &lt; 45 bpm &gt; 100 bpm ; An abnormal Screening ECG interpret Investigator clinically significant ; Used tobacco nicotinecontaining product ( eg , cigarette , cigar , chew tobacco , snuff ) product smoke cessation 2 week prior study drug administration confinement Clinical Research Unit ( CRU ) ; Treated investigational agent within 30 day Checkin ( Day 1 ) 5 halflives twice duration biological effect previous investigational drug ( whichever longer ) ; A positive history drug abuse positive result screen test drug ( ) abuse , ethanol , amphetamine , barbiturate , cocaine , opiates , benzodiazepine , cannabinoids , urine cotinine ( indicate active current smoking ) Screening Checkin ( Day 1 ) visit ; Poor peripheral venous access ; Deemed Investigator inappropriate study ; Any concurrent clinical condition judgment Investigator could either potentially pose health risk subject involve study could potentially influence study 's outcome .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>